Drugs / DTG/RPV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02373930 | Feb → Sep 2015 | HIV infectious disease | ViiV Healthcare | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTG/RPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02373930 ↗ |
| Known as | Product Code AK | “DTG/RPV 50 mg/25 mg: Product Code AK” NCT02373930 ↗ |
| Action | Inhibit | “Dolutegravir (DTG), a HIV-1 integrase inhibitor (INI), and Rilpivirine (RPV), a non-nucleoside HIV-1 reverse transcriptase inhibitor (NNRTI)” NCT02373930 ↗ |
| Route | Oral | “to be administered orally” NCT02373930 ↗ |